Last week, William Blair acted as an underwriter on three healthcare IPOs: Upstream Bio’s (NASDAQ:UPB) $293 million IPO, CAMP4 Therapeutics’ (NASDAQ: CAMP) $75 million IPO, and Ceribell’s (NASDAQ: CBLL) $207 million IPO. Congratulations to Upstream Bio, CAMP4 and Ceribell on the successful IPOs!
About the Companies
Upstream Bio, Inc., is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
CAMP4 Therapeutics Corp. is a clinical-stage biotechnology company pioneering the discovery and development of regulatory RNA-based therapeutics to treat a broad range of genetic diseases. The company’s lead product candidate, CMP-CPS-001, is an antisense oligonucleotide that has the potential to be the first disease-modifying therapy for the treatment of the most prevalent urea cycle disorders and is currently in a Phase 1 clinical trial.
Ceribell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions by becoming the standard of care for the detection and management of seizures through their FDA-approved, novel, point-of-care electroencephalography (EEG) platform. Combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Learn more about our biopharma and medical technology investment banking expertise.